Abstract
Glioblastoma is the most common and highly malignant brain tumor. It is also one among the most therapy-resistant human neoplasias. Patients die within a year of diagnosis despite the use of available treatment strategies such as surgery, radiotherapy, and chemotherapy. Thus, there is a critical need to find a novel therapeutic strategy for treating this disease. Here, we have investigated the molecular mechanisms for induction of apoptosis as well as for activation of immune components in human malignant glioblastoma T98G and U87MG cells following treatment with all-trans retinoic acid (ATRA) plus interferon-gamma (IFN-γ). Treatment of glioblastoma cells with ATRA alone prevented cell proliferation and induced astrocytic differentiation, while IFN-γ alone induced apoptosis and modulated expression of human leukocyte antigen (HLA) class II molecules such as HLA-DRα, HLA-DR complex, invariant chain (Ii), HLA-DM (an important catalyst of the class II-peptide loading), and gamma interferon-inducible lysosomal thiol-reductase (GILT). Interestingly, both T98G and U87MG cells showed more increase in apoptosis with expression of the HLA class II components for an effective immune response following treatment with ATRA plus IFN-γ than with IFN-γ alone. Apoptotic mode of cell death was confirmed morphologically by Wright staining and biochemically by measuring an increase in caspase-3 activity. While conversion of tumor cells into HLA class II+/Ii- cells by stimulation with the helper CD4+ T cells is thought to be challenging, this study reports for the first time that treatment of glioblastoma cells with ATRA plus IFN-γ can simultaneously enhance apoptosis and expression of the HLA class II immune components with a marked suppression of Ii expression. Taken together, this study suggests that induction of apoptosis and immune components of the HLA class II pathway by ATRA plus IFN-γ may be a promising chemoimmunotherapeutic strategy for treatment of human malignant glioblastoma.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS (2004) Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173:4352–4359
Anderson HA, Roche PA (1998) Phosphorylation regulates the delivery of MHC class II invariant chain complexes to antigen processing compartments. J Immunol 160:4850–4858
Arneson LS, Katz JF, Liu M, Sant AJ (2001) Hydrogen bond integrity between MHC class II molecules and bound peptide determines the intracellular fate of MHC class II molecules. J Immunol 167:6939–6946
Avva RR, Cresswell P (1994) In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1:763–774
Beers C, Burich A, Kleijmeer MJ, Griffith JM, Wong P, Rudensky AY (2005) Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol 174:1205–1212
Blum JS, Cresswell P (1988) Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 85:3975–3979
Brachet V, Raposo G, Amigorena S, Mellman I (1997) Ii chain controls the transport of major histocompatibility complex class II molecules to and from lysosomes. J Cell Biol 137:51–65
Busch R, Rinderknecht CH, Roh S, Lee AW, Harding JJ, Burster T, Hornell TM, Mellins ED (2005) Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev 207:242–260
Cetin N, Dienel G, Gokden M (2005) CD117 expression in glial tumors. J Neurooncol 75:195–202
Cresswell P (1996) Invariant chain structure and MHC class II function. Cell 84:505–507
Das A, Sribnick EA, Wingrave JM, Del Re AM, Woodward JJ, Appel SH, Banik NL, Ray SK (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81:551–562
Das A, Banik NL, Patel SJ, Ray SK (2004) Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 3:36
Das A, Garner DP, Del Re AM, Woodward JJ, Kumar DM, Agarwal N, Banik NL, Ray SK (2006) Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res 1084:146–157
Degener T, Momburg F, Moller P (1988) Differential expression of HLA-DR, HLA-DP, HLA-DQ and associated invariant chain (Ii) in normal colorectal mucosa, adenoma and carcinoma. Virchows Arch A Pathol Anat Histopathol 412:315–422
Denzin LK, Hammond C, Cresswell P (1996) HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 184:2153–2165
Denzin LK, Sant’Angelo DB, Hammond C, Surman MJ, Cresswell P (1997) Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278:106–109
Haque A, Blum JS (2005) New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J Biol Regul Homeost Agents 19:93–104
Haque MA, Hawes JW, Blum JS (2001) Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J Immunol 166:4543–4551
Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, Maric M, Cresswell P, Blum JS (2002) Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J Exp Med 195:1267–1277
Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245–3287
Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H (2005) EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7:717–722
Hong SJ, Kim TY, Kang SY, Yu JR, Song KY, Cho SY (2002) Clonorchis sinensis: immunolocalization of 26 kDa glutathione S-transferase in adult worms. Exp Parasitol 102:191–193
Hume DA, Fairlie DP (2005) Therapeutic targets in inflammatory disease. Curr Med Chem 12:2925–2929
Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344
Li P, Haque MA, Blum JS (2002) Role of disulfide bonds in regulating antigen processing and epitope selection. J Immunol 169:2444–2450
Lich JD, Jayne JA, Zhou D, Elliott JF, Blum JS (2003) Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. J Immunol 171:853–859
Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980–4986
Maric MA, Taylor MD, Blum JS (1994) Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 91:2171–2175
Matloubian M, Concepcion RJ, Ahmed R (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68:8056–8063
Mautner J, Jaffee EM, Pardoll DM (2005) Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 115:752–759
Mirandola P, Sponzilli I, Solenghi E, Micheloni C, Rinaldi L, Gobbi G, Vitale M (2006) Down-regulation of human leukocyte antigen class I and II and beta 2-microglobulin expression in human herpesvirus-7-infected cells. J Infect Dis 193:917–926
Nakagawa TY, Rudensky AY (1999) The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation. Immunol Rev 172:121–129
Nicholson MJ, Moradi B, Seth NP, Xing X, Cuny GD, Stein RL, Wucherpfennig KW (2006) Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol 176:4208–4220
Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11:2258–2264
O’Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS (2004) Induction of the antigen-processing enzyme IFN-γ-inducible lysosomal thiol reductase in melanoma cells is STAT1-dependent but CIITA-independent. J Immunol 173:731–735
Oldford SA, Robb JD, Watson PH, Drover S (2004) HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int J Cancer 112:399–406
Pallasch CP, Struss AK, Munnia A, Konig J, Steudel WI, Fischer U, Meese E (2005) Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 117:456–459
Pathak SS, Lich JD, Blum JS (2001) Editing of recycling class II: peptide complexes by HLA-DM. J Immunol 167:632–635
Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S (2000) T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:2209–2218
Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ (2004) Anomalous expression of the HLA-DR α and β chains in ovarian and other cancers. Cancer Biol Ther 3:1021–1027
Ray SK, Wilford GG, Crosby CV, Hogan EL, Banik NL (1999) Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. Brain Res 829:18–27
Roth W, Weller M (1999) Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 56:481–506
Rudensky AY, Maric M, Eastman S, Shoemaker L, DeRoos PC, Blum JS (1994) Intracellular assembly and transport of endogenous peptide-MHC class II complexes. Immunity 1:585–594
Shi B, Vinyals A, Alia P, Broceno C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A (2006) Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 38:544–562
Siegel RM (2006) Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 6:308–317
Simeone AM, Tari AM (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61:1475–1484
Sinnathamby G, Maric M, Cresswell P, Eisenlohr LC (2004) Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin. J Immunol 172:6607–6614
Skurkovich B (2002) Recommendations for parents adopting an infant with chronic hepatitis B. Pediatr Infect Dis J 21:1180–1181
Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151–160
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 66:1147–1154
van der Bruggen P, Van den Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18:98–104
Villarroel-Dorrego M, Speight PM, Barrett AW (2005) Expression of major histocompatibility complex class II and costimulatory molecules in oral carcinomas in vitro. Med Oral Patol Oral Cir Bucal 10:188–195
Weber DA, Dao CT, Jun J, Wigal JL, Jensen PE (2001) Transmembrane domain-mediated colocalization of HLA-DM and HLA-DR is required for optimal HLA-DM catalytic activity. J Immunol 167:5167–5174
Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H, Aguzzi A, Rammensee HG, Weller M (2002) Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 62:2592–2599
Zehbe I, Hohn H, Pilch H, Neukirch C, Freitag K, Maeurer MJ (2005) Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance. Int J Cancer 117:807–815
Acknowledgments
This work was supported in part by the grants from the National Institutes of Health (CA-91460, NS-31622 and NS-57811) and the state of South Carolina (SCIRF-0803), Leukemia and Lymphoma Society, American Cancer Society, Department of Defense, and American Lung Association. We also thank Dr. J. Blum for some of the antibodies and reagents.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haque, A., Das, A., Hajiaghamohseni, L.M. et al. Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol Immunother 56, 615–625 (2007). https://doi.org/10.1007/s00262-006-0219-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-006-0219-6